immuno-oncology therapy
Dec 29, 2023
HPK1 Inhibitors: A Promising Frontier in Immuno-Oncology Therapeutics
Hematopoietic progenitor kinase (HPK1) belongs to the family of Ste20 serine/threonine kinases known as mitogen-activated protein kinase kinase kinase kinase (MAP4K). It is primarily expressed in hematopoietic cells and functions as a negative regulator of T-cell receptor (TCR) and B-cell signaling, serving as an i...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
